Stock CIPLA CIPLA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Cipla Limited Stock

Equities

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-19 am EDT 		5-day change 1st Jan Change
1,346 INR -0.12% Intraday chart for Cipla Limited -3.65% +7.98%
Apr. 18 India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
Apr. 16 Cipla's Consumer Healthcare Arm to Acquire Ivia's Cosmetics, Personal-Care Marketing Business MT

Financials

Sales 2024 * 258B 3.09B Sales 2025 * 280B 3.35B Capitalization 1,088B 13.03B
Net income 2024 * 41.22B 494M Net income 2025 * 44.94B 538M EV / Sales 2024 * 3.99 x
Net cash position 2024 * 59.62B 714M Net cash position 2025 * 85.59B 1.03B EV / Sales 2025 * 3.58 x
P/E ratio 2024 *
26.4 x
P/E ratio 2025 *
24.1 x
Employees 32,323
Yield 2024 *
0.64%
Yield 2025 *
0.68%
Free-Float 64.49%
More Fundamentals * Assessed data

Chart Cipla Limited

Dynamic Chart

Latest news about Cipla Limited

India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
Cipla's Consumer Healthcare Arm to Acquire Ivia's Cosmetics, Personal-Care Marketing Business MT
Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks MT
Cipla Receives US FDA Observations Following Patalganga Facility Inspection MT
Cipla Gets Regulatory Nod to Merge US-Based Subsidiaries MT
Cipla to Distribute Sanofi's CNS Product Line in India MT
Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024 CI
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership CI
Losses Led by IT Drag Indian Equities on Tuesday MT
Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024 CI
Indian Equities Close with Marginal Gains on Tuesday as IT Stocks See Drop MT
Cipla Arm Completes Sale of Entire Stake in Wellthy MT
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Indian Equities Close Higher Midweek, Led by Banking, IT Stocks MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand RE
More news

Latest transcript on Cipla Limited

Logo Cipla Limited
Cipla Limited, Q3 2024 Earnings Call, Jan 25, 2024
More transcripts

Analyst Recommendations on Cipla Limited

Nomura Downgrades Cipla to Neutral From Buy, Price Target to INR1,427 From INR1,353 MT
Indian Equities End Strongly on Monday Ahead of Interim Budget, US Rate Decision MT
Jefferies Adjusts Cipla’s Price Target to INR1,250 From INR1,210, Keeps at Hold MT
Indian Equities Sink on Tuesday Amid Waning Hopes for US Rate Cuts MT
Nomura Adjusts Cipla's Price Target to INR1,353 from INR1,229, Keeps at Buy MT
More recommendations

Press releases Cipla Limited

Cipla : Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India PU
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives AQ
Cipla : Earnings Call Transcript Q2 FY24 PU
Cipla : launches drone-based delivery services for distribution of essential medicines for Hospitals and Pharmacies in Himachal Pradesh PU
Cipla : Address by Dr. Y K Hamied, Chairman at the 87th Annual General Meeting PU
More press releases

News in other languages on Cipla Limited

EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo
MERCK : L'Inde autorise le Molnupiravir
Planète Bourse : La revue de presse du mercredi 29 décembre 2021
L'Europe finit dans le rouge, l'aversion au risque se confirme
Point marchés-L'Europe finit dans le rouge, l'aversion au risque se confirme
More news

Quotes and Performance

1 day+0.23%
1 week-3.33%
Current month-9.79%
1 month-5.94%
3 months+1.69%
6 months+10.39%
Current year+8.35%
More quotes

Highs and lows

1 week
1 335.00
Extreme 1335
1 399.00
1 month
1 335.00
Extreme 1335
1 514.20
Current year
1 252.10
Extreme 1252.1
1 519.00
1 year
896.30
Extreme 896.3
1 519.00
3 years
850.00
Extreme 850
1 519.00
5 years
355.30
Extreme 355.3
1 519.00
10 years
355.30
Extreme 355.3
1 519.00
More quotes

Managers and Directors - Cipla Limited

Managers TitleAgeSince
Umang Vohra CEO
 Chief Executive Officer 52 15-09-30
Ashish Adukia DFI
 Director of Finance/CFO - 22-08-15
Geena Malhotra CTO
 Chief Tech/Sci/R&D Officer - 85-12-31
Members of the board TitleAgeSince
Ashok K. Sinha BRD
 Director/Board Member 72 13-07-15
Yusuf Khwaja Hamied CHM
 Chairman 87 72-07-20
Mustafa Khwaja Hamied BRD
 Director/Board Member 83 77-08-15
More insiders

ETFs positioned on Cipla Limited

Name Weight AuM 1st Jan change Investor Rating
WISDOMTREE INDIA EX-STATE-OWNED ENTERPRISES FUND ETF - USD ETF WisdomTree India ex-State-Owned Enterprises Fund ETF - USD
0.99% 6 M€ +6.07% -
More ETFs positioned on Cipla Limited

Quotes

Date Price Change Volume
24-04-19 1,346 -0.12% 1 173 025
24-04-18 1,347 -2.03% 2,974,196
24-04-16 1,375 -0.45% 1,433,760
24-04-15 1,381 -1.10% 1,125,072
24-04-12 1,397 -1.84% 2,190,583

Delayed Quote NSE India S.E., April 19, 2024 at 05:03 am EDT

More quotes

Company Profile

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2024-05-09 - Q4 2024 Earnings Release
Related indices
NIFTY 50 , NIFTY 100
More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,347 INR
Average target price
1,451 INR
Spread / Average Target
+7.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
CIPLA LIMITED Stock Cipla Limited
+8.35% 13.02B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.53% 43.54B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.96% 21.74B
SANDOZ GROUP AG Stock Sandoz Group AG
+5.03% 13.53B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+33.53% 11.28B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.05% 6.99B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+7.71% 5.09B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT. Stock Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
+3.49% 4.42B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CIPLA Stock